LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma.

Ilaria Cela Vito Carlo Alberto CaponioEmily CaponeMorena PintiMarco MascittiLucrezia TogniLorenzo Lo MuzioCorrado RubiniVincenzo De LaurenziRossano LattanzioVittoria PerrottiGianluca Sala

Published in: Oral diseases (2023)

The present study highlights that LGALS3BP is highly expressed in OSCC suggesting a role as a potential diagnostic biomarker and therapeutic target for ADC-based therapy.

Keyphrases

human health
risk assessment
computed tomography
cancer therapy
climate change